Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
NCT00542191Phase 2Terminated
- Sponsor
- Leo W. Jenkins Cancer Center
- Start
- Jul 2007
- Primary completion
- Aug 2016
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, cyclophosphamide, Paclitaxel Micelles for Injection, carboplatin in triple-negative breast cancer (TNBC), sponsored by Leo W. Jenkins Cancer Center. Started Jul 2007; status: terminated.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injectioncarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00542191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542191.